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Neutrophil-activating protein 1/interleukin 8 (NAP-1/IL-8)' was first identified
asa 72 amino acid peptide secreted by monocytes in response to bacterial LPS, with
the properties of activating and attracting polymorphonuclear leukocytes (PMN)
in vitro (1). Subsequently several different types ofcells, includingmacrophagesand
endothelial cells, were found to synthesize NAP-1/IL-8 upon stimulation with TNF
or IL-1 . Sequence data indicate that NAP-1/IL-8 is homologous to a group of pep-
tides including platelet basic protein, platelet factor 4, and macrophage inflamma-
tory protein 2 . In vivo accumulation ofPMN at sites of injection of NAP-1/IL-8
suggests that it may participate in the recruitment ofPMN into inflamed tissue,
and NAP-1/IL-8 has been identified in skin lesions of patients with psoriasis (1) .
Several lines of evidence indicate that the CD11/CD18 complex ofleukocyte adhe-
sion receptors may participate in the adhesion ofPMN to the vascular endothelium
which is necessary forextravasation . mAbs specific for CD18 are effective in blocking
the adherence of stimulated PMN to endothelium in vivo (2) and in vitro (3, 4),
and patients genetically deficient in the CDII/CD18 complex exhibit poor recruit-
ment of PMN to Rebuck skin windows (5). Here we describe the response of
CD11/CD18 onPMN to NAP-1/IL-8, with particular emphasis on the numerically
dominant member, CD11b/CD18 . This receptor not only recognizes ligands on en-
dothelium but also binds to complement protein C3bi (6), fibrinogen (7), and LPS (8).
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Materials and Methods
Reagents andBuffers.
￿
RecombinanthumanNAP-1/IL-8 (9)was generously supplied by the
Sandoz Research Institute, Vienna, Austria. Human fibrinogen depleted ofplasminogen was
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' Abbreviations used in this paper . AI, attachment index ; EC, endothelial cells ; fNLLP, formyl-norleucyl-
leucyl-phenylalanine ; HSA, humanserumalbumin; NAP-1/IL-8, neutrophil-activating protein 1/inter-
leukin 8 ; PDB, phorbol dibutyrate ; PI, phagocytic index ; PMN, polymorphonuclear leukocytes .
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a generous gift ofDr. Liliana Ossowski (The Rockefeller University, New York, NY). Fibro-
nectin was obtained from the New York Blood Center (New York, NY). fMLP, formyl-
norleucyl-leucyl-phenylalanine (fNLLP), PMA, phorbol dibutyrate (PDB), and aprotinin
were purchased from Sigma Chemical Co., St. Louis, MO. Pyrogen-free human serum al-
bumin (HSA) was supplied by Armour Pharmaceutical, Kankakee, IL. Buffers used were:
PBS (137 mM NaCl, 2 .7 mM KCI, 0.9 mM CaC12, 0.5 MM MgC12, and 8 mM phosphate,
pH 7.4); PD (PBS without CaC12 or MgC12 but with 0.02% NaN3); and HAP (pyrogen-
free PBS [Sigma], 0.05% glucose, 0.5 mg/ml HSA and 0.3 U/ml aprotinin).
Antibodies.
￿
mAb provided by colleagues were: OKM10, directed against CD11b (6), from
Dr. Gideon Goldstein (Ortho Pharmaceuticals, Rariton, NJ); LeuM5, directed against CDllc
(10), from Dr. Louis Lanier (Becton Dickinson & Co., Mountain View, CA); 543, directed
against CRl (11), from Dr. Robert Schreiber (Washington University, St. Louis, MO); and
T2G1, directed against fibrinogen (12), from Dr. Bohdan Kudryk (New York Blood Center,
New York, NY). 3G8, directed against Fcy receptor III (FcyRIII, CD16) (13); W6/32, di-
rected against HLA-A,B,C (14); and IB4, directed against CD18 (6), were as described.
Cell Preparation.
￿
Human PMN were isolated from freshly drawn, normal blood on Ficoll-
Hypaque gradients (15) and suspended at a final concentration of 2 x 106 cells/ml in HAP
buffer.
Cytoplasts were prepared from cytochalasin B-treated PMN exactly as described (16), washed
five times to remove the cytochalasin, and suspended to a concentration of 4 x 106/ml in
HAP buffer. Preparations of cytoplasts were previously characterized by enzyme assays and
electron microscopy to be free of granular constituents (4).
Flow Cytometry.
￿
Cells were exposed to mAb (5 1~g/ml in PD, 0.1 0 1o HSA) for 15 min at
0°C, washed, and incubated with fluoresceinated affinity-purified goat anti-mouse IgG
F(ab')2 (7 Itg/ml in PD, 0.1% HSA) (Tago Inc., Burlingame, CA) for 45 min at 0°C. Fluo-
rescence was measured on a Becton Dickinson FACScan cell analyzer. The mAb T2G1
(antifibrinogen) was used as a negative control in all experiments, and the mean fluorescence
channel derived from this antibody, which was the same as that obtained by omitting the
primary antibody, was subtracted from those of experimental samples.
Preparation ofOpsonized Erythrocytes.
￿
Sheep erythrocytes (E) were coated with IgG or IgM
as previously described (17). Erythrocytes coated with C3bi (EC3bi) were prepared by incu-
bating EIgM in C5-deficient human serum (SigmaChemical Co.) as described (18). Erythro-
cytes coated with the biosynthetic precursor ofLPS, lipid IVa, were prepared as described (8).
Assaysfor Attachment and Phagocytosis of Ligand-coated Erythrocytes.
￿
Assays for rosetting and
phagocytosis by adherent PMN or cytoplasts were essentially as previously described (17).
Monolayers of adherent cytoplasts were formed by plating the cytoplasts and centrifuging
the plates for 5 min at 150 g. The attachment index (AI) is the number oferythrocytes bound
per 100 PMN. The phagocytic index (PI) represents the number of erythrocytes ingested
by 100 PMN, counted after hypotonic lysis of uningested erythrocytes. Data are shown for
representative experiments, since variation between preparations ofPMN from different in-
dividuals precludes averaging of results.
Adhesion ofPMN to Fibrinogen-coated Surfaces.
￿
Adhesion of PMN to fibrinogen-coated sub-
strates was performed as described (7). The number of adherent PMN within a x40 field
were counted using a phase contrast microscope. All samples were run and counted in tripli-
cate and averaged.
Isolation andCulture ofHuman Endothelial Cells.
￿
Human umbilical vein endothelial cells (EC)
were isolated from fresh umbilical cords and cultured as previously described (4). Primary
EC cultures were subsequently seeded onto Terasaki plates that had been precoated with human
fibronectin, and EC were cultured for 2-3 d before use in adhesion assays. EC monolayers
were confluent by this time with typical cobblestone morphology, intact junctions (4), and
expression of factor VIII-related antigen (19).
Adhesion of PMN to EC.
￿
EC monolayers were fixed with 0.25% glutaraldehyde in PBS
at 4°C for 5 min, incubated with 50 mM glycine, 0 .15 M NaCl for 5 min, washed with PBS
four to five times, and stored at 4°C. Adhesion of PDB-stimulated PMN to fixed EC mono-
layers was CD18-dependent, since the adhesion was blocked by pretreating the PMN with
mAb IB4 (anti-CD18) (data not shown). The details of the adhesion assay have been pub-
lished elsewhere (4).Results and Discussion
NAP1/IL-8 Causes Increased Expression ofCDIIbICD18.
￿
The expression of CDllb/
CD18 on the surface of PMN as measured by flow cytometry increased in a
concentration-dependent manner in response to NAP-1/1L-8 (Fig. 1, stars). Theeffect
was apparent after exposure to 10-9 M NAP-1/IL-8, which appears to correspond
to the threshold concentration, and reached a maximum at 5 x 10-8 M. The av-
erage increase in expression of CDllb/CD18 observed over several experiments was
2.9-fold, with a range of 2.1-4.9-fold. The expression of CDllb/CD18 in response
to 5 x 10-8 M NAP-1/1L-8 was rapid, reaching a plateau by 15 min and remaining
at that level for at least 90 min (Fig. 2, open circles). These results areconsistent with
the observation that NAP-1/IL-8 induces therapid secretion ofspecific granules from
PMN (20), and specific granules serve as intracellular storage compartments for
CDllb/CD18 (21). Maximum upregulation of CDllb/CD18 was observed at concen-
trations of NAP-1/IL-8 that induce PMN chemotaxis, a rise in cytosolic free cal-
cium, granule exocytosis (22, 23), and transient actin polymerization (Detmers, P.,
unpublished observations).
The expression of CDllc/CD18 (p150,95) and CR1 increased on average 2.0-fold
in response to 5 x 10 -8 M NAP-1/IL-8 (range 1.7-2.7-fold and 1.5-2.3-fold, respec-
tively) (data not shown). Upregulation of CRl was very rapid and reached a max-
imum by 15 min (data not shown), consistent with the rapid release of a separate
vesicular compartment (Morel, F., and B. Dewald unpublished observations). No
change was observed for HLA-A,B,C (range 1.0-1.1), while FcYRIII exhibited a very
slight increase in expression, or in some cases, no change at all (average 1.1-fold,
range 1.0-1.6-fold) (data not shown).
NAP-1/IL-8Enhances theBindingActivities ofCDIIbICD18. Attachment ofEON.
￿
Freshly
isolated PMNbind fewEC3bi, butincreased bindingofEC3bi wasobserved at con-
centrations of NAP-1/1L-8 as low as 10-9 M, and 5 x 10 -8 M NAP-1/1L-8 caused
the AI to increase on average 10 .9-fold (range 1.3-37.0-fold) (Fig. 1, closed circles).
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Underthe same conditions binding ofEIgG increased slightly in response to NAP-1/
IL-8 (average of 1.5-fold, range 1.0-1.9) (Figure 1, squares).
Binding of EC3bi also increased an average of 5.3-fold in response to 5 x 10-8
MfMLP (range 1.3-20.7-fold) (Fig. 1, open circles). We previously reported that fmLP
caused enhanced phagocytosis of EIgG and increased expression of CDllb/CD18
without a rise the binding activity of CDllb/CD18 (24). These observations were
made repeatedly with asingle batch offMLP that mayhave been chemically modified
in such away as to give a result that does not represent a normal response to formyl
peptides. Our present observations of strong enhancement of the binding activity
of CDllb/CD18 by fMLP were obtained with a different batch of fmLP and have
been confirmed by similar results with adifferent formyl peptide, fNLLP (data not
shown).
Binding of EC3bi in response to NAP-1/IL-8 increased rapidly and appeared to
reach a plateau by 15 min (Fig. 2, squares). In some experiments we observed a bi-
phasic response with afurther increase in binding of EC3bi between 30 and 60 min.
Increased Expression of CD11b1CD18 is Not Necessaryfor Enhanced Binding ofEC3bi.
￿
We
used PMN cytoplasts to determine if ligand binding was enhanced by NAP-1/IL-8
in the absence of newly expressed receptors. Flow cytometry with mAbs OKM10
(antiCD11b) and LeuM5 (anti CD11c) confirmedthat neitherof these two receptors
increasedon the cytoplast surface in response to NAP-1/IL-8 (datanot shown). How-
ever, NAP-1/IL-8 increased the bindingof EC3bi to cytoplasts about threefoldwithout
changing the attachment ofEIgG (Table I). Thus, increasedexpression ofCDllb/CD18
is not required to observe enhanced ligand-binding activity in response to NAP-
1/IL-8, and the cytokine must therefore cause a qualitative change in CDllb/CD18
on the cell surface. One possible mechanism for increased receptor avidity in the
absence ofincreased receptor expression is receptor aggregation. CD11b/CD18 moves
into small aggregates on PMN in response to stimuli that enhance bindingof EC3bi
.
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TABLE I
NAP-1/IL-8 Stimulated Binding of EON by PMN Cytoplasts
Cytoplasts were incubated for a total of 60 min at 37°C with HAP buffer or
NAP-1/1L-8 with EC3bi added for the final 30 min of the incubation. AI is
described in Materials and Methods.
(24), and the time course ofaggregationcorresponds precisely with the time course
of increased binding of C3bi (24) or EC (4).
NAFUIL-8 Does Not Promote Phagocytosis ofEON.
￿
In six separate experiments,
1 h of incubation at 37 °C with concentrations of NAP-1/IL-8 ranging from 10 -9
to 10-7 Mfailed to induce phagocytosis ofEC3bi, although ingestion ofEIgG was
the same as in controls or slightly enhanced (average increase of 1.3-fold in the PI
at 5 x 10-8 MNAP-1/IL-8 [range 1.0-2.0]) (data not shown). NAP-1/IL-8 was there-
fore capable ofstimulating ligand binding by CD11b/CD18 without promoting the
signals required to accomplish phagocytosis .
NAP-UIL-8 Enhances the Binding ofLPS to PMN.
￿
CDllb/CD18 recognizes LPS
through a binding site that is distinct from that which binds C3bi (25). 5 x 10-8 M
NAP-1/IL-8 increased the binding oferythrocytes coated with the biosynthetic pre-
cursor of LPS, lipid IVa (EIVa), by an average of 16.1-fold (range 4-50-fold), and
a large enhancement of EIVa binding was observed at concentrations as low as
10-9 M (Fig. 1, triangles). NAP-1/IL-8 thus stimulated two different ligand-binding
activities of CDllb/CD18. This represents the first description ofregulation of the
LPS-bindingactivity ofCDll/CD18, andthis enhanced abilityofPMN to recognize
LPS could improve antimicrobial defense.
NAFUIL-8Enhances BindingofPMNto Fibrinogen.
￿
CDllb/CD18 recognizes a por-
tion ofthe y-chain offibrinogen containing the amino acid sequence Lys-Glu-Ala-
Gly-AspVal (KQAGDV) (7). NAP-1/IL-8 at a concentration of 5 x 10 -8 M in-
creased the binding ofPMN to fibrinogen immobilized on plastic substrates by an
averageof4.3-fold (range 1.6-9.4-fold), whileithad no effect on thebindingofPMN
to control, HSA-coated substrates (Table II). NAP-1/IL-8 may thus accelerate the
interaction of PMN with fibrin deposits at sites of tissue injury.
NAP-UIL-8Stimulates Binding ofPMNto Endothelium.
￿
At a concentration of 5 x
10-8 M NAP-1/IL-8, PMN adherence to unstimulated EC increased on average 1.6-
fold (Table II). Incontrast, PDB caused an average 3.4-fold increase in PMN adher-
ence, indicating that NAP-1/IL-8 was a relatively mild stimulus ofPMN-EC inter-
action. Theseresultsconfirm those obtainedbyothers (26). SinceEC maybe stimu-
latedto synthesize NAP-1/IL-8(1), local secretion ofNAP-1/IL-8maypromotesufficient
adhesion of PMN to EC in inflamed tissue to enable transmigration to occur.
Exp.
Concentration of
NAP-1/1L-8
Attachment
EC3bi
index'
EIgG
1 None 67 114
10-8 M 157 129
5 x 10 -8 M 187 106
2 None 35 364
10 -$ M 112 315
5 x 10-8 M 107 3281160
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TABLE II
NAP-1/IL-8 Enhanced Adhesion of PMN to Fibrinogen-coated
Substrates and EC Monolayers
` PMN were addedwith NAP-1/IL-8 or HAPbuffer to Terasaki plates coated with fibrinogen
or pyrogen-free HSA for60 min at 37°C. PMA-treated PMN were incubated for 15 min
at 37°C . Nonadherent cells were removed by washing, and the adherent cells were fixed
in glutaraldehyde before counting.
i Fluorescent PMNchallenged with NAP-1/IL-8 or PDBwere added to EC monolayers and
coincubated for15 minat 37°C . Unattached PMNwere removedby washing, and adherent
PMN were quantitated with an inverted microscope equipped for epifluorescence.
Summary
The cytokine NAP-1/IL-8 is produced by a variety of different cells in response
to inflammatory stimuli and elicits several biological responses from PMN. Experi-
ments presented here demonstrate that PMN exposed to NAP-1/IL-8 expressed in-
creased amounts ofCDllb/CD18, as well as CDllc/CD18 and CR1, on theircell sur-
face, while expression of FcyRIII and HLA-A,B,C remained essentially unchanged.
Increased CD11b/CD18 and CDllc/CD18 appears to correspond with the release of
specific granules by NAP-1/IL-8 . NAP-1/IL-8 was also a potent stimulator ofseveral
of the binding activities of CDllb/CD18. Ligation of EC3bi by CDllb/CD18 was
rapidly enhanced by NAP-1/IL-8, but phagocytosis of the ligated particles was not
induced by the agonist. In addition, enhanced binding of EC3bi was observed in
the absence of an increase in receptor expression as shown with PMN cytoplasts.
NAP-1/IL-8 promoted additional adhesive interactions between CDllb/CD18 and
the biosynthetic precursor of LPS, lipid IVa, fibrinogen, and endothelial cells, sug-
gesting that NAP-1/IL-8 may promote leukocyte adhesion in vivo that could lead
to recruitment of PMN to sites of tissue inflammation.
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Conditions
fibrinogen`
adherent
HSA
Adhesion to
(PMN
per field)
Fibrinogen Exp. 1
Adhesion to ECI
(PMN adherent per mm2)
Exp. 2 Exp. 3 Exp. 4
No stimulus 25 30 235 168 232 596
NAP-1/IL-8
1 x 10-9 M - - 290 234 258 635
1 x 10-8 M 44 83 345 258 423 668
5 x 10-e M 35 137 325 300 447 880
1 x 10-7 M 35 116 320 252 341 905
PMA, 33 ng/ml 32 230
PDB, 300 ng/ml - - 680 798 856 1,440DETMERS ET AL.
￿
116 1
References
1 . Baggiolini, M., A. Walz, and S. L. Kunkel. 1989. NAP-1/IL-8, a novel cytokine that acti-
vates neutrophils. J. Clin. Invest. 84:1045.
2 . Arfors, K.-E., C. Lundberg, L. Lindblom, K. Lundberg, P G. Beatty, andJ. M. Harlan.
1987 . A monoclonal antibody to the membrane glycoprotein complex CD18 inhibits poly-
morphonuclear leukocyte accumulation and plasma leakage in vivo. Blood. 69:338.
3 . Harlan, J. M., P D. Killen, F. M. Senecal, B. R. Schwartz, E. K. Yee, F. R. Taylor,
P G. Beatty, T H. Price, and H. D. Ochs. 1985. The role of neutrophil membrane glyco-
protein GP-150 in neutrophil adhesion to endothelium in vitro. Blood. 66:167.
4. Lo, S. K., P. A. Detmers, S. M. Levin, and S. D. Wright. 1989. Transient adhesion of
neutrophils to endothelium. f. Exp. Med. 169:1779.
5 . Todd, R. F, III, and D. R. Freyer. 1988. The CDIl/CD181eukocyte glycoprotein deficiency.
Hematol.10ncol. Clin. N. Am. 2:13 .
6. Wright, S. D., P. E. Rao, W. C. Van Voorhis, L. S. Craigmyle, K. lida, M. A. Talle,
E. F. Westberg, G. Goldstein, and S. C. Silverstein. 1983 . Identification of the C3bi re-
ceptor on human monocytes and macrophages by using monoclonal antibodies. Proc.
Nail. Acad Sci. USA. 80:5699.
7 . Wright, S. D., J. I. Weitz, A. J. Huang, S. M. Levin, S. C. Silverstein, andJ. D. Loike.
1988. Complement receptor type three (CDllb/CD18) ofhuman polymorphonuclear leu-
kocytes recognizes fibrinogen. Proc. Nail. Acad Sci. USA. 85 :7734.
8. Wright, S. D., and M. T. C. Jong. 1986. Adhesion-promoting receptors on human mac-
rophages recognize E. coli by binding to lipopolysaccharide. J. Exp. Med. 164:1876.
9. Lindley, I., H. Aschauer, J .-M. Seifert, C. Lam, W. Brunowsky, E. Kownatzki, M. Thelen,
P. Peveri, B. Dewald, V. VonTscharner, A. Walz, and M. Baggiolini. 1988. Synthesis and
expression in Escherichia coli ofthe gene encoding monocyte-derived neutrophil-activating
factor: Biological equivalence between natural and recombinant neutrophil-activating
factor. Proc. Nail. Acad Sci. USA. 85:9199.
10. Lanier, L. L., M. A. Arnaout, R. Schwarting, N. L. Warner, and G. D. Ross. 1985.
p150/95, Third member of the LFA-/CR3 polypeptide family identified by anti-Leu M5
monoclonal antibody. Eur. J. Immunol. 15:713 .
11 . Esparza, I., R. I. Fox, and R. D. Schreiber. 1986. Interferon-gamma-dependent modu-
lation ofC3b receptors (CRI) on human peripheral blood monocytes.f. Immunol. 136:1360.
12 . Kudryk, B., A. Rohaza, M. Ahadi, J . Chin, and M. E. Wiebe. 1984. Specificity of a
monoclonal antibody for the NH2-terminal region of fibrin. Mol. Immunol. 21:89.
13 . Fleit, H. B., S. D. Wright, and J . C. Unkeless. 1982 . Human neutrophil Fcy receptor
distribution and structure. Proc. Nail. Acad Sci. USA. 79:3275.
14. Barnstable, C . J., W. F. Bodmer, G. Brown, G. Galfre, C. Milstein, A. F. Williams, and
A. Zeigler. 1978. Production of monoclonal antibodies to group A erythrocytes, HLA
and other human cell surface antigens. New tools for genetic analysis. Cell. 14:9.
15 . English, D., and B. R. Anderson. 1974. Single-step separation of red blood cells, granu-
locytes, and mononuclear phagocytes on discontinuous density gradients of Ficoll-
Hypaque. J. Immunol. Methods. 5:249 .
16. Roos, D., A. A. Voetman, and L. J. Meerhor. 1983. Functional activity of enucleated
human polymorphonuclear leukocytes. J. Cell Biol. 97 :368.
17 . Wright, S. D., and S. C . Silverstein. 1982 . Tumor-promoting phorbol esters stimulate
C3b and C3b' receptor-mediated phagocytosis in cultured human monocytes. J. Exp.
Med. 156:1149.
18. Wright, S. D., P S. Tobias, R. J. Ulevitch, and R. A. Ramos. 1989. Lipopolysaccharid e
binding protein opsonizes LPS-bearing particles for recognition by a novel receptor on1162
￿
NAP-1/IL-8 STIMULATES CD116/CD18 ON NEUTROPHILS
macrophages. J. Exp. Med. 170:1231.
19 . Pawlowski, N. A., E. L. Abraham, S. Pontier, W. A. Scott, and Z. A. Cohn. 1985. Human
monocyte-endothelial cell interaction in vitro. Proc. Nall. Acad. Sci. USA. 82:8208.
20 . Walz, A., B. Dewald, V. VonTscharner, and M. Baggiolini. 1989. Effects of the neutrophil-
activating peptide NAP-2, platelet basic protein, connective tissue-activating peptide 3,
and platelet factor 4 on human neutrophils. J. Exp. Med. 170:1745.
21 . Bainton, D. F., L. J. Miller, T. K. Kishimoto, and T. A. Springer. 1987. Leukocyte adhe-
sion receptors are stored in peroxidase-negative granules of human neutrophils. j Exp.
Med. 166:1641 .
22 . Peveri, P, A. Walz, B. Dewald, and M. Baggiolini. 1988. A novel neutrophil-activating
factor produced by human mononuclear phagocytes. f. Exp. Med. 167:1547.
23 . Thelen, M., P Peveri, P Kernen, V. VonTscharner, A. Walz, and M. Baggiolini. 1988.
Mechanism of neutrophil activation by NAF, a novel monocyte-derived peptide agonist.
FASEB (Fed. Am. Soc. Exp. BioL) j 2:2702.
24. Detmers, P A., S. D. Wright, E. Olsen, B. Kimball, and Z. A. Cohn. 1987. Aggregation
of complement receptors on human neutrophils in the absence of ligand. J. Cell Biol.
105:1137.
25. Wright, S. D., S. M. Levin, M. T. C. Jong, Z. Chad, and L. G. Kabbash. 1989. CR3
(CDllb/CD18) expresses one binding site for Arg-Gly-Asp-containing peptides, and a
second site for bacterial lipopolysaccharide. J. Exp. Med. 169:175.
26. Carveth, H. J., J. F. Bohnsack, T M. McIntyre, M. Baggiolini, S. M. Prescott, and
G. A. Zimmerman. 1989. Neutrophil activating factor (NAF) induces polymorphonu-
clear leukocyte adherence to endothelial cells and to subendothelial matrix proteins. Bio-
chem. Biophys. Res. Commun. 162 :387.